Delve into Labiotech's October oncology roundup and find out about the news that caught our attention this last month.

Discover five myopia companies racing to go beyond glasses, as myopia is set to affect half the world by 2050.

Learn when TIDE-based Sanger sequencing can replace NGS for measuring on-target gene editing efficiency in regulated ...

Delve into the field of B7-H3 ADCs, a new contender in SCLC cancer, as Hansoh Pharma and Medilink bring momentum with ...

Explore the preclinical research catching our eye in October 2026, from AI drug design to small molecules and gene therapy ...

Known for its freezing winters, Finland is warming up to global entrepreuners and investors to boost its life science ...

Three big bets in metabolic disease: the race to challenge Lilly and Novo, a pill that mimics exercise, and a gene therapy ...

Discover Novo's pipeline in 2026, as it recently set out a new plan to reach $23 billion in risk-adjusted pipeline sales by ...

As the standards of care for prostate cancer change, new drugs, combination therapies, and trials enter the therapeutic space ...

In June, AstraZeneca once again turned to the Chinese company CSPC Pharmaceuticals, with whom it initially entered into an exclusive license agreement in October 2024 for an early-stage cardiovascular ...

California-based Cargo Therapeutics has had a rough year with its CAR-T cell therapy firicabtagene autoleucel being discontinued after patients experienced toxic side effects in the clinic. The ...